Cart
sales@molnova.com
Dihydrocucurbitacin B
CAS No. 13201-14-4
Dihydrocucurbitacin B( 23,24-dihydrocucurbitacin B )
Catalog No. M29129 CAS No. 13201-14-4
Dihydrocucurbitacin B is isolated from the roots of Cayaponia tayuya with anti-cancer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 138 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 336 | In Stock |
|
| 25MG | 537 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihydrocucurbitacin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionDihydrocucurbitacin B is isolated from the roots of Cayaponia tayuya with anti-cancer activity.
-
DescriptionDihydrocucurbitacin B is isolated from the roots of Cayaponia tayuya with anti-cancer activity.(In Vitro):Dihydrocucurbitacin B inhibits NFAT and delayed-type hypersensitivity and induces cell cycle arrest in the G0 phase.
-
In Vitro——
-
In Vivo——
-
Synonyms23,24-dihydrocucurbitacin B
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorIL Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number13201-14-4
-
Formula Weight560.728
-
Molecular FormulaC32H48O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@@]12C[C@H](O)C(=O)C(C)(C)C1=CC[C@@]1([H])[C@]3(C)C[C@@H](O)[C@H]([C@@](C)(O)C(=O)CCC(C)(C)OC(C)=O)[C@@]3(C)CC(=O)[C@@]21C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Sarilumab
Sarilumab （SAR-153191）is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.
-
Spesolimab
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.
-
Vunakizumab
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .
